Ranbaxy temporarily stops API supply from two plants

Ranbaxy Laboratories Ltd has announced that it has temporarily putting on hold shipments from company's Active Pharmaceutical Ingredients (API) facilities of the Toansa and Dewas plants as the company is currently examining processes and controls at all its API manufacturing and quality units.
 
“This voluntary decision was taken as a precautionary measure and out of abundant caution to better allow the company to assess and review the processes and controls. The company will resume shipments after reassuring them about the processes and controls at these facilities,” said Ranbaxy in a BSE filing.
 
Ranbaxy has constituted a committee of the Board in February 2014 as the ‘Quality & Integrity Committee’. The committee's objective is to help and assure good governance to all Ranbaxy stakeholders. “Its primary role is to provide oversight on the company's manufacturing and quality operations, systems, organisation and integrity,” said the BSE filing.